Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a study of gefitinib plus olaparib gefitinib in combination with olaparib (AZD2281)
versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation
positive advanced non-small-cell lung cancer.